Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ira Oliff"'
Autor:
Hani M. Babiker, Julie Poore, Allyson J. Ocean, Ely Benaim, Ira Oliff, Drew W. Rasco, Jaime R. Merchan, Eloy Roman, Vincent Chung, Ravi Kumar Paluri
Publikováno v:
Journal of Clinical Oncology. 36:396-396
396 Background: RX-3117 is an oral small-molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by uridine cytidine kinase 2. RX-3117 has shown efficacy in xenograft models of gemcitabine resistant pancreatic, bladder and colorec
Autor:
Elizabeth Crowley, Linda T. Vahdat, Randa Loutfi, Rebecca Bechhold, Robert Weaver, Michael Yellin, Dennis Citrin, Thomas Hawthorne, Thomas A. Davis, Scott Cruickshank, Francis P. Arena, Denise A. Yardley, Andres Forero, Michelle E. Melisko, Ira Oliff, Mansoor N. Saleh, Alison Stopeck, Tessa Cigler, Agustin A. Garcia, Jennifer Green
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(14)
Purpose Glycoprotein NMB (gpNMB), a negative prognostic marker, is overexpressed in multiple tumor types. Glembatumumab vedotin is a gpNMB-specific monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin E. This phase II study in
Autor:
Judith S. Ochs, Michael K. Wolf, Vincent A. Miller, Joan H. Schiller, Giorgio V. Scagliotti, Steven D. Averbuch, James A. Reeves, Rafael Rosell, Ronald B. Natale, Roy S. Herbst, David H. Johnson, Abderrahim Fandi, John Grous, Annetta D. Krebs, Ira Oliff, Christian Manegold, Giuseppe Giaccone
Publikováno v:
Journal of Clinical Oncology. 22:785-794
Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance antitumor efficacy of cytotoxics, and combination with paclita